Alzheimer’s drug firm shares slide as Samsung denies €33.6bn takeover bid

Biogen has struggled to push its controversial Alzheimer’s treatment in recent months

Biogen has struggled to push its controversial Alzheimer’s treatment in recent months. File picture: Pexels

Biogen shares fell after Samsung denied a Korean media report that the US drugmaker was in talks to sell itself to the company.

The stock fell almost 7% at one stage, erasing the gains made after an article from the Korea Economic Daily, which said that the Cambridge, Massachusetts-based biotechnology company had approached Samsung about a takeover.